ROVI reported FY 2025 total revenue of EUR 756.1 million (down 1%) and revenue of EUR 743.5 million (down 3%), with the decline mainly driven by its contract development and manufacturing business, while specialty pharmaceutical sales rose 11% to EUR 473.9 million. Gross profit was EUR 494.7 million (up 3%), with gross margin at 66.5% (up 3.9 percentage points), and EBITDA increased 4% to EUR 216.2 million (EBITDA margin 29.1%, up 1.9 percentage points). Net profit rose 3% to EUR 140.4 million, and the company said it will propose a dividend of EUR 0.9594 per share. Key product and business highlights included Okedi sales of EUR 56.7 million (up 97%), heparin franchise sales of EUR 266.8 million (up 7%) including enoxaparin sales of EUR 157.7 million (up 9%), and Neparvis sales of EUR 56.7 million (up 10%). ROVI also announced a definitive collaboration agreement with Roche for the manufacture of a new medicine in clinical development, and said it expects the deal to contribute to a minimum increase of between 20% and 25% in contract manufacturing sales in 2030 versus the 2024 figure. Separately, ROVI’s unit ROIS Phoenix entered into an asset purchase agreement with Bristol Myers Squibb to acquire a Phoenix, Arizona manufacturing facility, alongside a toll manufacturing agreement with an initial five-year term that provides for a minimum payment of USD 50 million per year, with closing expected in H1 2026. In Spain, ROVI signed a 10-year agreement with Sandoz to market Rolcya and began commercialization in November 2025, targeting annual sales of EUR 10 million to EUR 15 million. For FY 2026, ROVI expects revenue to increase by between a high single-digit and low double-digit percentage versus FY 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laboratorios Farmacéuticos ROVI SA published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.